Clinical trials: Rheumatoid Arthritis, completed
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not…
- Trial name
- OSKIRA - 2 (NCT01197534)
- Testing
- fostamatinib
- Where
- 149 sites in United States, Canada and 14 more
- Volunteers
- 913 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy
This is a randomized, double-blind, multi-center, parallel-group study to evaluate the efficacy and safety of subcutaneous (SC) tocilizumab (162 milligrams [mg] every 2 weeks [Q2W]) given as monotherapy and in combination with…
- Trial name
- NCT03155347
- Testing
- Tocilizumab, MTX
- Where
- 20 sites in China
- Volunteers
- 340 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study in Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to…
- Trial name
- RA-BEAM (NCT01710358)
- Testing
- Adalimumab, Baricitinib, Methotrexate
- Where
- 213 sites in United States, Argentina and 26 more
- Volunteers
- 1,307 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
The study aims to evaluate the predictability of early response to Certolizumab pegol in combination with Methotrexate at one year in patients with moderate to severe rheumatoid arthritis.
- Trial name
- SPEED (NCT01443364)
- Testing
- Certolizumab pegol
- Where
- 18 sites in Italy
- Volunteers
- 132 people
- Sponsor
- UCB Italy s.p.a.
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
The primary objectives of this study is to assess the safety, tolerability and efficacy of multiple doses of the mavrilimumab (CAM-3001) administered subcutaneously in subjects with moderately active Rheumatoid Arthritis (RA).
- Trial name
- NCT01050998
- Testing
- Mavrilimumab 10 mg, Mavrilimumab 30 mg, Mavrilimumab 50 mg
- Where
- 55 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 516 people
- Sponsor
- MedImmune LLC
Xerostomia, Sjogren's Syndrome
Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome
The purpose of this study is to evaluate the effectiveness of NGX267 in the improvement of decreased salivary flow associated with primary or secondary Sjögren's syndrome.
- Trial name
- NCT00637793
- Testing
- NGX267
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- TorreyPines Therapeutics
Degenerative Osteoarthritis, Rheumatoid Arthritis
Orthopilot Elite Post-Market Clinical Follow-Up
Prospective, multicenter, observational, comparative clinical trial on the equivalence of two different OrthoPilot® navigation system generations applied for computer-assisted total knee arthroplasty
- Conditions
- Degenerative Osteoarthritis, Rheumatoid Arthritis, Posttraumatic Arthropathy, Instability, Joint
- Trial name
- NCT03817632
- Testing
- Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1, Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
- Where
- 3 sites in Germany
- Volunteers
- 217 people
- Sponsor
- Aesculap AG
Rheumatoid Arthritis, Plaque Psoriasis
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
The study will estimate the preference of rheumatoid arthritis (RA) and Plaque Psoriasis (PsO) patients who self inject etanercept for one of two experimental autoinjectors.
- Trial name
- NCT01875991
- Testing
- Etanercept via Autoinjector A, Etanercept via Autoinjector B
- Where
- 37 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Amgen
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
This is a two part study comparing CHS-0214 to Enbrel in patients with active rheumatoid arthritis and an inadequate response with Methotrexate (MTX) who are naive to biologic therapies.
- Trial name
- CHS-0214-02 (NCT02115750)
- Testing
- Etanercept, CHS-0214
- Where
- 141 sites in United States, Belarus and 10 more
- Volunteers
- 647 people
- Sponsor
- Coherus Oncology, Inc.
Rheumatoid Arthritis
A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis
This is a multicenter, randomized, double-blind phase2 study to evaluate the safety and investigate the efficacy of YRA-1909 in Patients with Rheumatoid Arthritis who are on a stable dose of Methotrexate(MTX) and who have an…
- Trial name
- NCT03275025
- Testing
- YRA-1909 low dose, YRA-1909 mid dose, YRA-1909 high dose
- Where
- 14 sites in South Korea
- Volunteers
- 116 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
Rheumatoid Arthritis
Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)
Efficacy and Safety Study of MK0359 in Patients with Arthritis
- Trial name
- NCT00482417
- Testing
- MK0359
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis
The overall objective of the study is to assess the effectiveness of switching from immediate-release prednisone (conventional) therapy to delayed-release prednisone (RAYOS) in patients with moderately to severely active…
- Trial name
- SUNRAY (NCT02287610)
- Testing
- RAYOS (delayed-release prednisone)
- Volunteers
- 75 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
An observational, non-interventional study on social, economic and quality-of-life outcomes of Adalimumab use in participants with moderate to severe active Rheumatoid Arthritis.
- Trial name
- RELIVE (NCT01387789)
- Where
- 13 sites in Malaysia
- Volunteers
- 71 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF
This study will assess the onset and maintenance of effect of tocilizumab on relief in patients with active moderate or severe rheumatoid arthritis who have had an inadequate response to DMARDs or anti-TNF.
- Trial name
- NCT00977106
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 22 sites in France
- Volunteers
- 103 people
- Sponsor
- Hoffmann-La Roche
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Rheumatoid Arthritis
Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study
This is a Phase 2, multicenter, 24-week OLE study to assess the safety and tolerability of ABT-122 in participants with rheumatoid arthritis (RA) who had had an inadequate response to methotrexate (MTX) therapy and who completed…
- Trial name
- NCT02433340
- Testing
- ABT-122
- Volunteers
- 158 people
- Sponsor
- AbbVie
Active Rheumatoid Arthritis
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
The purpose of this study is to compare the efficacy and safety of adalimumab produced by CinnaGen company and AbbVie adalimumab in subjects with active Rheumatoid Arthritis.
- Trial name
- NCT03172325
- Testing
- Adalimumab, Methotrexate, Folic Acid
- Where
- 10 sites in Iran
- Volunteers
- 136 people
- Sponsor
- Cinnagen
Rheumatoid Arthritis
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA).
- Trial name
- NCT00721123
- Testing
- Tocilizumab
- Where
- 69 sites in Argentina, Australia and 15 more
- Volunteers
- 538 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Primary Objective: To demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) were effective for: reduction of signs and symptoms at Week 24 and improvement of physical function at Week 12 in…
- Trial name
- NCT01709578
- Testing
- Sarilumab, hydroxychloroquine, methotrexate
- Where
- 196 sites in United States, Argentina and 28 more
- Volunteers
- 546 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.